Drug Profile
Research programme: haematological cancer therapeutics - Genfit/LFB
Latest Information Update: 13 Feb 2008
Price :
$50
*
At a glance
- Originator Genfit; LFB
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 13 Feb 2008 Discontinued for Haematological malignancies in France (unspecified route)
- 03 May 2006 Early research is ongoing
- 11 Mar 2003 Early research in Haematological malignancies in France (unspecified route)